{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:21:14Z","timestamp":1791512474686,"version":"4.3.4"},"reference-count":240,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"U.S. Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["1 R01 HL155261"],"award-info":[{"award-number":["1 R01 HL155261"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["RIBEIR20P0"],"award-info":[{"award-number":["RIBEIR20P0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["WOLFGA19G0"],"award-info":[{"award-number":["WOLFGA19G0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["MUHLEB 22A0"],"award-info":[{"award-number":["MUHLEB 22A0"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["FFC 10\/2022"],"award-info":[{"award-number":["FFC 10\/2022"]}]},{"name":"Italian Cystic Fibrosis Research Foundation","award":["FFC 7\/2019"],"award-info":[{"award-number":["FFC 7\/2019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a new series of therapeutics that correct and potentiate some classes of mutations of the CFTR, have provided a great therapeutic advantage to people with cystic fibrosis (pwCF). The main hindrances of the present CFTR modulators are related to their limitations in reducing chronic lung bacterial infection and inflammation, the main causes of pulmonary tissue damage and progressive respiratory insufficiency, particularly in adults with CF. Here, the most debated issues of the pulmonary bacterial infection and inflammatory processes in pwCF are revisited. Special attention is given to the mechanisms favoring the bacterial infection of pwCF, the progressive adaptation of Pseudomonas aeruginosa and its interplay with Staphylococcus aureus, the cross-talk among bacteria, the bronchial epithelial cells and the phagocytes of the host immune defenses. The most recent findings of the effect of CFTR modulators on bacterial infection and the inflammatory process are also presented to provide critical hints towards the identification of relevant therapeutic targets to overcome the respiratory pathology of pwCF.<\/jats:p>","DOI":"10.3390\/ijms24055010","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:49:08Z","timestamp":1678074548000},"page":"5010","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-7060","authenticated-orcid":false,"given":"Carla M. P.","family":"Ribeiro","sequence":"first","affiliation":[{"name":"Marsico Lung Institute\/Cystic Fibrosis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-4980","authenticated-orcid":false,"given":"Matthew G.","family":"Higgs","sequence":"additional","affiliation":[{"name":"Marsico Lung Institute\/Cystic Fibrosis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne S.","family":"Muhlebach","sequence":"additional","affiliation":[{"name":"Marsico Lung Institute\/Cystic Fibrosis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-6470","authenticated-orcid":false,"given":"Matthew C.","family":"Wolfgang","sequence":"additional","affiliation":[{"name":"Marsico Lung Institute\/Cystic Fibrosis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-2496","authenticated-orcid":false,"given":"Monica","family":"Borgatti","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Innthera4CF, Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1972-7766","authenticated-orcid":false,"given":"Ilaria","family":"Lampronti","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Innthera4CF, Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Cabrini","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Innthera4CF, Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: Chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: Genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"ref_4","unstructured":"(2022, December 20). CFTR2. Available online: https:\/\/cftr2.org."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2014.06.005","article-title":"New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls","volume":"145","author":"Bell","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0031-3955(16)30074-8","article-title":"Mucoviscidosis and the celiac syndrome","volume":"1","author":"Shwachman","year":"1954","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/352628a0","article-title":"Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene","volume":"352","author":"Tabcharani","year":"1991","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1073\/pnas.91.12.5340","article-title":"Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator","volume":"91","author":"Poulsen","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41591-021-01332-7","article-title":"Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition","volume":"27","author":"Carraro","year":"2021","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.202008-3198OC","article-title":"Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia","volume":"203","author":"Okuda","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/thx.2006.062190","article-title":"A morphometric study of mucins and small airway plugging in cystic fibrosis","volume":"62","author":"Burgel","year":"2007","journal-title":"Thorax"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ppul.21154","article-title":"Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?","volume":"45","author":"Tiddens","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32227","DOI":"10.1074\/jbc.M110.155259","article-title":"The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel","volume":"285","author":"Gentzsch","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/363263a0","article-title":"CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship","volume":"363","author":"Gabriel","year":"1993","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thoraxjnl-2015-207588","article-title":"Airway surface liquid homeostasis in cystic fibrosis: Pathophysiology and therapeutic targets","volume":"71","author":"Haq","year":"2016","journal-title":"Thorax"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-Obstructive Lung Diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1164\/rccm.201301-0059CI","article-title":"Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease","volume":"188","author":"Knowles","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ccm.2016.04.008","article-title":"Primary Ciliary Dyskinesia","volume":"37","author":"Knowles","year":"2016","journal-title":"Clin. Chest Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/archdischild-2019-317687","article-title":"Clinical features and management of children with primary ciliary dyskinesia in England","volume":"105","author":"Rubbo","year":"2020","journal-title":"Arch. Dis. Child."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.chest.2022.02.052","article-title":"Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis","volume":"162","author":"Roehmel","year":"2022","journal-title":"Chest"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1183\/09031936.97.10102376","article-title":"Longitudinal study of lung function in a cohort of primary ciliary dyskinesia","volume":"10","author":"Ellerman","year":"1997","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1378\/chest.129.1.118","article-title":"Mucus properties in children with primary ciliary dyskinesia: Comparison with cystic fibrosis","volume":"129","author":"Bush","year":"2006","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ra46","DOI":"10.1126\/scisignal.2003755","article-title":"Mechanosensitive ATP release maintains proper mucus hydration of airways","volume":"6","author":"Button","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","volume":"124","author":"Henderson","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1002\/ppul.24530","article-title":"Mucus, mucins, and cystic fibrosis","volume":"54","author":"Morrison","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1801297","DOI":"10.1183\/13993003.01297-2018","article-title":"Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH","volume":"52","author":"Hill","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"L306","DOI":"10.1152\/ajplung.2001.281.2.L306","article-title":"Lung disease in cystic fibrosis: Is airway surface liquid composition abnormal?","volume":"281","author":"Verkman","year":"2001","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eaav3488","DOI":"10.1126\/scitranslmed.aav3488","article-title":"Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis","volume":"11","author":"Esther","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_32","first-page":"S5","article-title":"Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway","volume":"54","author":"Mall","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.pcl.2016.04.003","article-title":"Cystic Fibrosis: Microbiology and Host Response","volume":"63","author":"Zemanick","year":"2016","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomized controlled trial","volume":"140","author":"Stutman","year":"2002","journal-title":"J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/adc.70.2.84","article-title":"Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period","volume":"70","author":"Weaver","year":"1994","journal-title":"Arch. Dis. Child."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2012.04.004","article-title":"Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care","volume":"11","author":"Rosenfeld","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1038\/s41598-019-42751-4","article-title":"Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis","volume":"9","author":"Simonin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","unstructured":"Cystic Fibrosis Foundation (2017). Patient Registry 2016 Annual Data Report, Cystic Fibrosis Foundation."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcf.2021.08.009","article-title":"Longitudinal changes and regional variation of incident infection rates at cystic fibrosis centers, United States 2010\u20132016","volume":"21","author":"Muhlebach","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jama.293.5.581","article-title":"Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis","volume":"293","author":"Li","year":"2005","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/cid\/ciu385","article-title":"Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis","volume":"59","author":"Ramsey","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/thoraxjnl-2018-212616","article-title":"Help, hinder, hide and harm: What can we learn from the interactions between Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections?","volume":"74","author":"Limoli","year":"2019","journal-title":"Thorax"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fcimb.2017.00106","article-title":"In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.","volume":"7","author":"Hotterbeekx","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1007\/s00253-016-7596-3","article-title":"Interactions between Pseudomonas aeruginosa and Staphylococcus aureus during co-cultivations and polymicrobial infections","volume":"100","author":"Nguyen","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1469-0691.2011.03742.x","article-title":"Prevalence and genetic diversity of Staphylococcus aureus small-colony variants in cystic fibrosis patients","volume":"19","author":"Yagci","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S2213-2600(19)30365-0","article-title":"Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): A multicentre, observational study","volume":"7","author":"Wolter","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijmm.2018.02.003","article-title":"Staphylococcus aureus in the airways of cystic fibrosis patients\u2014A retrospective long-term study","volume":"308","author":"Schwerdt","year":"2018","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.0602138103","article-title":"Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients","volume":"103","author":"Smith","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1165\/rcmb.2003-0260OC","article-title":"Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5","volume":"30","author":"Adamo","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12088","DOI":"10.1073\/pnas.94.22.12088","article-title":"Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung","volume":"94","author":"Pier","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrmicro2199","article-title":"The type III secretion system of Pseudomonas aeruginosa: Infection by injection","volume":"7","author":"Hauser","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.trsl.2008.10.003","article-title":"Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: A paradigm of chronic infection","volume":"152","author":"Jain","year":"2008","journal-title":"Transl. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Tran, C.S., Rangel, S.M., Almblad, H., Kierbel, A., Givskov, M., Tolker-Nielsen, T., Hauser, A.R., and Engel, J.N. (2014). The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004479"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1128\/JCM.43.8.3956-3962.2005","article-title":"Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis","volume":"43","author":"Corech","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1099\/00221287-146-10-2531","article-title":"Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of exoS","volume":"146","author":"Kaufman","year":"2000","journal-title":"Microbiology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"41326","DOI":"10.1074\/jbc.M302472200","article-title":"In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors","volume":"278","author":"Phillips","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.femsle.2005.06.044","article-title":"Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosa invasion","volume":"250","author":"Cowell","year":"2005","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/IAI.73.3.1695-1705.2005","article-title":"Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection","volume":"73","author":"Lee","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41467-021-23451-y","article-title":"Compensatory evolution of Pseudomonas aeruginosa\u2019s slow growth phenotype suggests mechanisms of adaptation in cystic fibrosis","volume":"12","author":"Rossi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijmm.2006.01.036","article-title":"A network of networks: Quorum-sensing gene regulation in Pseudomonas aeruginosa","volume":"296","author":"Schuster","year":"2006","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1074\/jbc.272.15.9884","article-title":"Inhibitors and specificity of Pseudomonas aeruginosa LasA","volume":"272","author":"Kessler","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/thoraxjnl-2017-210298","article-title":"Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator- IL-6-antimicrobial-repair pathway","volume":"73","author":"Villeret","year":"2018","journal-title":"Thorax"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3389\/fimmu.2018.01675","article-title":"Pseudomonas aeruginosa LasB Subverts Alveolar Macrophage Activity by Interfering With Bacterial Killing Through Downregulation of Innate Immune Defense, Reactive Oxygen Species Generation, and Complement Activation","volume":"9","author":"Bastaert","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molmed.2004.10.002","article-title":"The role of pyocyanin in Pseudomonas aeruginosa infection","volume":"10","author":"Lau","year":"2004","journal-title":"Trends Mol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1462-5822.2006.00696.x","article-title":"Pseudomonas aeruginosa pyocyanin inactivates lung epithelial vacuolar ATPase-dependent cystic fibrosis transmembrane conductance regulator expression and localization","volume":"8","author":"Kong","year":"2006","journal-title":"Cell. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1165\/ajrcmb.26.5.4489","article-title":"Early mitochondrial dysfunction, superoxide anion production, and DNA degradation are associated with non-apoptotic death of human airway epithelial cells induced by Pseudomonas aeruginosa exotoxin A","volume":"26","author":"Plotkowski","year":"2002","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/IAI.01390-08","article-title":"Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication","volume":"77","author":"Bonhoure","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1128\/IAI.00338-07","article-title":"The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator","volume":"75","author":"MacEachran","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1107\/S1744309109047599","article-title":"Purification, crystallization and preliminary X-ray diffraction analysis of Cif, a virulence factor secreted by Pseudomonas aeruginosa","volume":"66","author":"Bahl","year":"2010","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"L150","DOI":"10.1152\/ajplung.00383.2017","article-title":"An epoxide hydrolase secreted by Pseudomonas aeruginosa decreases mucociliary transport and hinders bacterial clearance from the lung","volume":"314","author":"Hvorecny","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bomberger, J.M., Maceachran, D.P., Coutermarsh, B.A., Ye, S., O\u2019Toole, G.A., and Stanton, B.A. (2009). Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000382"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1074\/jbc.M113.459271","article-title":"Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation","volume":"289","author":"Bomberger","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijmm.2015.11.001","article-title":"Possible mechanisms of Pseudomonas aeruginosa-associated lung disease","volume":"306","author":"Silva","year":"2016","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1440-1843.2010.01819.x","article-title":"Pseudomonas aeruginosa: Host defence in lung diseases","volume":"15","author":"Williams","year":"2010","journal-title":"Respirology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tim.2005.05.011","article-title":"Modulation of lung epithelial functions by Pseudomonas aeruginosa","volume":"13","author":"Lau","year":"2005","journal-title":"Trends Microbiol."},{"key":"ref_78","first-page":"363","article-title":"Cystic fibrosis respiratory infections: Interactions between bacteria and host defence","volume":"52","year":"1997","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0952-7915(99)80005-3","article-title":"Antimicrobial peptides in mammalian and insect host defence","volume":"11","author":"Lehrer","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s000180050004","article-title":"Epithelial antimicrobial peptides: Innate local host response elements","volume":"56","year":"1999","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbadis.2011.12.012","article-title":"Oxidative stress and antioxidant therapy in cystic fibrosis","volume":"1822","author":"Galli","year":"2012","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.mib.2009.06.018","article-title":"Role of reactive oxygen species in antibiotic action and resistance","volume":"12","author":"Dwyer","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1469-0691.2010.03250.x","article-title":"Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance","volume":"16","author":"Oliver","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7910","DOI":"10.1128\/JB.01147-08","article-title":"Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation","volume":"190","author":"Mena","year":"2008","journal-title":"J. Bacteriol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1128\/IAI.73.4.2550-2553.2005","article-title":"Pseudomonas aeruginosa OxyR is required for full virulence in rode and insect models of infection and for resistance to human neutrophils","volume":"73","author":"Lau","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1099\/13500872-145-6-1349","article-title":"Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: A mechanism for virulence activation in the cystic fibrosis lung","volume":"145","author":"Mathee","year":"1999","journal-title":"Microbiology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1164\/ajrccm\/140.6.1650","article-title":"Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration","volume":"140","author":"Baltimore","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e0029122","DOI":"10.1128\/msphere.00291-22","article-title":"Effects of Mucin and DNA Concentrations in Airway Mucus on Pseudomonas aeruginosa Biofilm Recalcitrance","volume":"7","author":"Rouillard","year":"2022","journal-title":"mSphere"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1165\/rcmb.2021-0359OC","article-title":"Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence","volume":"67","author":"Batson","year":"2022","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/iai.62.2.596-605.1994","article-title":"Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis","volume":"62","author":"Mahenthiralingam","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ben Mohamed, F., Garcia-Verdugo, I., Medina, M., Balloy, V., Chignard, M., Ramphal, R., and Touqui, L. (2012). A crucial role of Flagellin in the induction of airway mucus production by Pseudomona aeruginosa. PLoS ONE, 7.","DOI":"10.1371\/annotation\/7718a413-90cf-4183-9eb0-3a1b7c5bcd83"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"161","DOI":"10.15698\/mic2021.07.755","article-title":"LasR-regulated proteases in acute vs. chronic lung infection: A double-edged sword","volume":"8","author":"Hennemann","year":"2021","journal-title":"Microb. Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1152\/jappl.1989.67.1.316","article-title":"Effect of pyocyanin and 1-hydroxyphenazine on in vivo tracheal mucusvelocity","volume":"67","author":"Munro","year":"1989","journal-title":"J. Appl. Physiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/mi.2015.119","article-title":"Pseudomonas aeruginosa pyocyanin modulates mucin glycosylation with sialyl-Lewis(x) to increase binding to airway epithelial cells","volume":"9","author":"Jeffries","year":"2016","journal-title":"Mucosal Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/glycob\/9.8.757","article-title":"Pseudomonas aeruginosa binds to neoglycoconjugates bearing mucin carbohydrate determinants and predominantly to sialyl-Lewis x conjugates","volume":"9","author":"Scharfman","year":"1999","journal-title":"Glycobiology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/iai.62.5.1896-1900.1994","article-title":"Pseudomonas aeruginosa outer membrane adhesins for human respiratory mucus glycoproteins","volume":"62","author":"Carnoy","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Riquelme, S.A., and Prince, A. (2021). Pseudomonas aeruginosa Consumption of Airway Metabolites Promotes Lung Infection. Pathogens, 10.","DOI":"10.3390\/pathogens10080957"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/JB.187.15.5267-5277.2005","article-title":"Cystic fibrosis sputum supports growth and cues aspects of Pseudomonas aeruginosa physiology","volume":"187","author":"Palmer","year":"2005","journal-title":"J. Bacteriol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2020.00385","article-title":"Pulmonary Pathogens Adapt to Immune Signaling Metabolites in the Airway","volume":"11","author":"Riquelme","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"790574","DOI":"10.3389\/fimmu.2021.790574","article-title":"Immunometabolites Drive Bacterial Adaptation to the airway","volume":"12","author":"Tomlinson","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12931-020-01591-x","article-title":"Airway immunometabolites fuel Pseudomonas aeruginosa infection","volume":"21","author":"Riquelme","year":"2020","journal-title":"Respir. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.immuni.2017.11.010","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity","volume":"47","author":"Riquelme","year":"2017","journal-title":"Immunity"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaav4634","DOI":"10.1126\/scitranslmed.aav4634","article-title":"CFTR-PTEN-dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection","volume":"11","author":"Riquelme","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/JB.182.2.425-431.2000","article-title":"The global carbon metabolism regulator Crc is a component of a signal transduction pathway required for biofilm development by Pseudomonas aeruginosa","volume":"182","author":"Gibbs","year":"2000","journal-title":"J. Bacteriol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1128\/jb.173.15.4700-4706.1991","article-title":"Isolation and characterization of catabolite repression control mutants of Pseudomonas aeruginosa PAO","volume":"173","author":"Wolff","year":"1991","journal-title":"J. Bacteriol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrmicro1932","article-title":"Carbon catabolite repression in bacteria: Many ways to make the most out of nutrients","volume":"6","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1574-6976.2010.00218.x","article-title":"Carbon catabolite repression in Pseudomonas: Optimizing metabolic versatility and interactions with the environment","volume":"34","author":"Rojo","year":"2010","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.21037\/atm.2019.12.49","article-title":"Succinate links mitochondria to deadly bacteria in cystic fibrosis","volume":"7","author":"Esposito","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.cmet.2020.04.017","article-title":"Pseudomonas aeruginosa Utilizes Host-Derived Itaconate to Redirect Its Metabolism to Promote Biofilm Formation","volume":"31","author":"Riquelme","year":"2020","journal-title":"Cell Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e148548","DOI":"10.1172\/JCI148548","article-title":"The role of itaconate in host defense and inflammation","volume":"132","author":"Peace","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcf.2006.12.001","article-title":"Early inflammation in the airways of a cystic fibrosis foetus","volume":"6","author":"Verhaeghe","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_113","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1165\/ajrcmb.23.2.4214","article-title":"Inflammation and infection in naive human cystic fibrosis airway grafts","volume":"23","author":"Tirouvanziam","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1164\/rccm.202102-0451OC","article-title":"Early Lung Disease Exhibits Bacteria-Dependent and -Independent Abnormalities in Cystic Fibrosis Pigs","volume":"204","author":"Bouzek","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mi.2012.17","article-title":"Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation","volume":"5","author":"Kelly","year":"2012","journal-title":"Mucosal Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1055\/s-0039-1694021","article-title":"Cystic Fibrosis: Pathophysiology of Lung Disease","volume":"40","author":"Bergeron","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: An update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: A mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1600903","DOI":"10.1183\/13993003.00903-2016","article-title":"Hypoxia and sterile inflammation in cystic fibrosis airways: Mechanisms and potential therapies","volume":"49","author":"Montgomery","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/thoraxjnl-2011-200912","article-title":"Progression of early structural lung disease in young children with cystic fibrosis assessed using CT","volume":"67","author":"Mott","year":"2012","journal-title":"Thorax"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"Pillarisetti","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1172\/JCI125669","article-title":"IL-1\u03b2 dominates the promucin secretory cytokine profile in cystic fibrosis","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/mi.2012.105","article-title":"The ER stress transducer IRE1\u03b2 is required for airway epithelial mucin production","volume":"6","author":"Martino","year":"2013","journal-title":"Mucosal Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Ng, H.P., Zhou, Y., Song, K., Hodges, C.A., Drumm, M.L., and Wang, G. (2014). Neutrophil-mediated phagocytic host defense defect in myeloid Cftr-inactivated mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106813"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1189\/jlb.0412188","article-title":"Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection","volume":"92","author":"Bonfield","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcf.2012.11.004","article-title":"Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst","volume":"12","author":"Houston","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1172\/JCI0213572","article-title":"Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis","volume":"109","author":"Vandivier","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Simonin-Le Jeune, K., Le Jeune, A., Jouneau, S., Belleguic, C., Roux, P.F., Jaguin, M., Dimanche-Boitre, M.T., Lecureur, V., Leclercq, C., and Desrues, B. (2013). Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075667"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000446825","article-title":"Cystic Fibrosis Lung Immunity: The Role of the Macrophage","volume":"8","author":"Bruscia","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"10935","DOI":"10.1038\/s41598-020-67729-5","article-title":"Altered iron metabolism in cystic fibrosis macrophages: The impact of CFTR modulators and implications for Pseudomonas aeruginosa survival","volume":"10","author":"Hazlett","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2003502","DOI":"10.1183\/13993003.03502-2020","article-title":"Targeting cystic fibrosis inflammation in the age of CFTR modulators: Focus on macrophages","volume":"57","author":"Gillan","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: In vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/rccm.201207-1346OC","article-title":"Th17\/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines","volume":"187","author":"Iannitti","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/rccm.201407-1381OC","article-title":"Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomona infection","volume":"191","author":"Hector","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2021.05.001","article-title":"Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis","volume":"20","author":"Beckert","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"102214","DOI":"10.1016\/j.coph.2022.102214","article-title":"Overview of CF lung pathophysiology","volume":"64","author":"Cabrini","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ppul.24004","article-title":"Increased cytokines in cystic fibrosis patients\u2019 upper airways during a new P. aeruginosa colonization","volume":"53","author":"Jaudszus","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcf.2020.12.022","article-title":"Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis","volume":"20","author":"Frey","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Coates, M.S., Alton, E.W.F.W., Rapeport, G.W., Davies, J.C., and Ito, K. (2021). Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246050"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Parker, D., and Prince, A. (2013). Epithelial uptake of flagella initiates proinflammatory signaling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059932"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"10714","DOI":"10.1073\/pnas.1721270115","article-title":"Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions","volume":"115","author":"Schick","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"fny026","DOI":"10.1093\/femsle\/fny026","article-title":"Diversification of Pseudomonas aeruginosa within the cystic fibrosis lung and its effects on antibiotic resistance","volume":"365","author":"Clark","year":"2018","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcf.2019.04.009","article-title":"Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung","volume":"18","author":"Malhotra","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1126\/science.286.5444.1561","article-title":"Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa","volume":"286","author":"Ernst","year":"1999","journal-title":"Science"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1086\/521367","article-title":"Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis","volume":"196","author":"Ernst","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni777","article-title":"Human Toll-like receptor 4 recognizes host-specific LPS modifications","volume":"3","author":"Hajjar","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/09680519030090060201","article-title":"Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4","volume":"9","author":"Ernst","year":"2003","journal-title":"J. Endotoxin Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-90-481-9078-2_11","article-title":"The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection","volume":"53","author":"Moskowitz","year":"2010","journal-title":"Subcell. Biochem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00441-017-2753-2","article-title":"Partners in crime: Neutrophils and monocytes\/macrophages in inflammation and disease","volume":"371","author":"Nicholls","year":"2018","journal-title":"Cell Tissue Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"L198","DOI":"10.1152\/ajplung.90472.2008","article-title":"Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia","volume":"296","author":"Kurahashi","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/IAI.68.7.4289-4296.2000","article-title":"CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia","volume":"68","author":"Tsai","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/IAI.00501-09","article-title":"Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia","volume":"77","author":"Koh","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/CMR.16.4.597-621.2003","article-title":"Infections in patients with inherited defects in phagocytic function","volume":"16","author":"Andrews","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1701910","DOI":"10.1183\/13993003.01910-2017","article-title":"Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis","volume":"51","author":"Dittrich","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1378\/chest.129.5.1148","article-title":"Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis","volume":"129","author":"Kim","year":"2006","journal-title":"Chest"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"13502","DOI":"10.1074\/jbc.RA119.009934","article-title":"Exposure of Pseudomonas aeruginosa to bactericidal hypochlorous acid during neutrophil phagocytosis is compromised in cystic fibrosis","volume":"294","author":"Dickerhof","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"105994","DOI":"10.1016\/j.rmed.2020.105994","article-title":"BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization","volume":"170","author":"Hovold","year":"2020","journal-title":"Respir. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"659523","DOI":"10.3389\/fimmu.2021.659523","article-title":"Bactericidal\/Permeability-Increasing Protein Preeminently Mediates Clearance of Pseudomonas aeruginosa In Vivo via CD18-Dependent Phagocytosis","volume":"12","author":"Theprungsirikul","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2013.07.019","article-title":"Log reduction of multidrug-resistant Gram-negative bacteria by the neutrophil-derived recombinant bactericidal\/permeability-increasing protein","volume":"42","author":"Weitz","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1021\/bi970177e","article-title":"Mechanisms of action of bactericidal\/permeability-increasing protein BPI on reconstituted outer membranes of gram-negative bacteria","volume":"36","author":"Wiese","year":"1997","journal-title":"Biochemistry"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2007.07.005","article-title":"The bactericidal\/permeability-increasing protein (BPI) in infection and inflammatory disease","volume":"384","author":"Schultz","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1084\/jem.192.7.1069","article-title":"LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells","volume":"192","author":"Yang","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"ftaa048","DOI":"10.1093\/femspd\/ftaa048","article-title":"Activity of airway antimicrobial peptides against cystic fibrosis pathogens","volume":"78","author":"Cabak","year":"2020","journal-title":"Pathog. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm-22-617","article-title":"The effects of LL-37 on virulence factors related to the quorum sensing system of Pseudomonas aeruginosa","volume":"10","author":"Xiao","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Cigana, C., Curcur\u00f9, L., Leone, M.R., Ieran\u00f2, T., Lor\u00e8, N.I., Bianconi, I., Silipo, A., Cozzolino, F., Lanzetta, R., and Molinaro, A. (2009). Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008439"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1083\/jcb.201006052","article-title":"Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps","volume":"191","author":"Papayannopoulos","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1128\/IAI.00922-06","article-title":"Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa","volume":"74","author":"Sonawane","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.172.1.509","article-title":"Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host response-inducing activity","volume":"172","author":"Espinola","year":"2004","journal-title":"J. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fmicb.2015.00630","article-title":"The absence of the Pseudomonas aeruginosa OprF protein leads to increased biofilm formation through variation in c-di-GMP level","volume":"6","author":"Bouffartigues","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_173","first-page":"77","article-title":"Faecal Calprotectin","volume":"39","author":"Pathirana","year":"2018","journal-title":"Clin. Biochem. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","article-title":"Calprotectin: From biomarker to biological function","volume":"70","author":"Jukic","year":"2021","journal-title":"Gut"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2010.01.005","article-title":"Sputum and serum calprotectin are useful biomarkers during CF exacerbation","volume":"9","author":"Gray","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"13372","DOI":"10.1021\/jacs.9b11950","article-title":"Calcium Binding to the Innate Immune Protein Human Calprotectin Revealed by Integrated Mass Spectrometry","volume":"142","author":"Adhikari","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"fnac071","DOI":"10.1093\/femsle\/fnac071","article-title":"Zinc-binding metallophores protect Pseudomonas aeruginosa from calprotectin-mediated metal starvation","volume":"369","author":"Ammendola","year":"2022","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"17132","DOI":"10.1038\/s41598-017-16765-9","article-title":"Pseudomonas aeruginosa zinc uptake in chelating environment is primarily mediated by the metallophore pseudopaline","volume":"7","author":"Lhospice","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"11951","DOI":"10.1038\/ncomms11951","article-title":"The innate immune protein calprotectin promotes Pseudomonas aeruginosa and Staphylococcus aureus interaction","volume":"7","author":"Wakeman","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10156-011-0287-1","article-title":"Inhibitory effects of lactoferrin on biofilm formation in clinical isolates of Pseudomonas aeruginosa","volume":"18","author":"Kamiya","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1086\/423821","article-title":"Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis","volume":"190","author":"Rogan","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Cutone, A., Lepanto, M.S., Rosa, L., Scotti, M.J., Rossi, A., Ranucci, S., De Fino, I., Bragonzi, A., Valenti, P., and Musci, G. (2019). Aerosolized Bovine Lactoferrin Counteracts Infection, Inflammation and Iron Dysbalance in A Cystic Fibrosis Mouse Model of Pseudomonas aeruginosa Chronic Lung Infection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092128"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1128\/IAI.00418-13","article-title":"Pseudomonas aeruginosa uses multiple pathways to acquire iron during chronic infection in cystic fibrosis lungs","volume":"81","author":"Konings","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1164\/rccm.201404-0681OC","article-title":"Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes","volume":"190","author":"Rosenfeld","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1128\/JB.01491-14","article-title":"Adaptation of iron homeostasis pathways by a Pseudomonas aeruginosa pyoverdine mutant in the cystic fibrosis lung","volume":"196","author":"Nguyen","year":"2014","journal-title":"J. Bacteriol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e00966-e14","DOI":"10.1128\/mBio.00966-14","article-title":"Within-host evolution of Pseudomonas aeruginosa reveals adaptation toward iron acquisition from hemoglobin","volume":"5","author":"Marvig","year":"2014","journal-title":"mBio"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(19)32676-5","article-title":"Entering the era of highly effective CFTR modulator therapy","volume":"394","author":"Zemanick","year":"2019","journal-title":"Lancet"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid Improvement after Starting Elexacaftor-Tezacaftor- Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Steinack, C., Ernst, M., Beuschlein, F., Hage, R., Roeder, M., Schuurmans, M.M., Schmid, C., and Gaisl, T. (2023). Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis. J. Cyst. Fibros.","DOI":"10.1016\/j.jcf.2023.01.004"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1093\/nar\/gkab488","article-title":"Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung","volume":"49","author":"Dang","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.coph.2017.09.017","article-title":"The suppression of premature termination codons and the repair of splicing mutations in CFTR","volume":"34","author":"Oren","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Keegan, D.E., and Brewington, J.J. (2021). Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094448"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/rccm.202002-0369OC","article-title":"Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR","volume":"202","author":"Birket","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"L1093","DOI":"10.1152\/ajplung.00082.2021","article-title":"Ivacaftor partially corrects airway inflammation in a humanized G551D rat","volume":"320","author":"Green","year":"2021","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"102235","DOI":"10.1016\/j.coph.2022.102235","article-title":"Animal models of cystic fibrosis in the era of highly effective modulator therapies","volume":"64","author":"Grubb","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Ludovico, A., Moran, O., and Baroni, D. (2022). Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911396"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2100185","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e122695","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jcf.2017.10.006","article-title":"Ion channels as targets to treat cystic fibrosis lung disease","volume":"17","author":"Martin","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e0314821","DOI":"10.1128\/mbio.03148-21","article-title":"Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"576293","DOI":"10.3389\/fphar.2020.576293","article-title":"Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis","volume":"11","author":"Perrem","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2017.04.014","article-title":"Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens","volume":"50","author":"Payne","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e0408322","DOI":"10.1128\/spectrum.04083-22","article-title":"Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis","volume":"11","author":"Cigana","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.202004-0991OC","article-title":"Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis","volume":"202","author":"Schupp","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3389\/fphar.2020.01219","article-title":"CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis","volume":"11","author":"Hisert","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Cavinato, L., Luly, F.R., Pastore, V., Chiappetta, D., Sangiorgi, G., Ferrara, E., Baiocchi, P., Mandarello, G., Cimino, G., and Del Porto, P. (2022). Elexacaftor- Tezacaftor-Ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis. Eur. Respir. J., 2200725.","DOI":"10.1183\/13993003.00725-2022"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"20","author":"Zhang","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1165\/rcmb.2019-0032OC","article-title":"Transcriptomic Responses to Ivacaftor and Prediction of Ivacaftor Clinical Responsiveness","volume":"61","author":"Sun","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jcf.2020.12.023","article-title":"Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor","volume":"20","author":"Einarsson","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"17798","DOI":"10.1074\/jbc.M410618200","article-title":"Chronic airway infection\/inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia","volume":"280","author":"Ribeiro","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1074\/jbc.M410617200","article-title":"Cystic fibrosis airway epithelial Ca2+ i signaling: The mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia","volume":"280","author":"Ribeiro","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1085\/jgp.200308893","article-title":"The mitochondrial barriers segregate agonist-induced calcium-dependent functions in human airway epithelia","volume":"122","author":"Ribeiro","year":"2003","journal-title":"J. Gen. Physiol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1089\/ars.2014.6223","article-title":"Mitochondria-associated membranes: Composition, molecular mechanisms, and physiopathological implications","volume":"22","author":"Giorgi","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"eaax9093","DOI":"10.1126\/sciadv.aax9093","article-title":"Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis","volume":"6","author":"Rimessi","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2174\/156652412801318791","article-title":"Endoplasmic reticulum stress in chronic obstructive lung diseases","volume":"12","author":"Ribeiro","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Ribeiro, C.M., and Lubamba, B.A. (2017). Role of IRE1\u03b1\/XBP-1 in Cystic Fibrosis Airway Inflammation. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010118"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"14904","DOI":"10.1074\/jbc.M809180200","article-title":"Airway epithelial inflammation-induced endoplasmic reticulum Ca2+ store expansion is mediated by X-box binding protein-1","volume":"284","author":"Martino","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"102258","DOI":"10.1016\/j.coph.2022.102258","article-title":"Functional role of the ER stress transducer IRE1\u03b1 in CF airway epithelial inflammation","volume":"65","author":"Ribeiro","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1801133","DOI":"10.1183\/13993003.01133-2018","article-title":"The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model","volume":"52","author":"Gentzsch","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"628722","DOI":"10.3389\/fphar.2021.628722","article-title":"Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies","volume":"12","author":"Gentzsch","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Ribeiro, C.M.P., and Gentzsch, M. (2021). Impact of Airway Inflammation on the Efficacy of CFTR Modulators. Cells, 10.","DOI":"10.3390\/cells10113260"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"e150398","DOI":"10.1172\/JCI150398","article-title":"Inflammatory cytokines TNF-\u03b1 and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators","volume":"131","author":"Rehman","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e164944","DOI":"10.1172\/jci.insight.164944","article-title":"Airway surface hyperviscosity and defective mucociliar transport by IL-17\/TNF-\u03b1 are corrected by \u03b2-adrenergic stimulus","volume":"7","author":"Guidone","year":"2022","journal-title":"JCI Insight."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fcell.2020.00058","article-title":"TGF-\u03b21 Augments the Apical Membrane Abundance of Lemur Tyrosine Kinase 2 to Inhibit CFTR-Mediated Chloride Transport in Human Bronchial Epithelia","volume":"8","author":"Cruz","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Snodgrass, S.M., Cihil, K.M., Cornuet, P.K., Myerburg, M.M., and Swiatecka-Urban, A. (2013). Tgf-\u03b21 inhibits Cftr biogenesis and prevents functional rescue of \u0394F508-Cftr in primary differentiated human bronchial epithelial cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063167"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Cabrini, G. (2022). CFTR Modulators and Reduction of Airway Inflammation in Cystic Fibrosis: How Much is Enough?. Curr. Med. Chem., 14.","DOI":"10.2174\/0929867330666221014110730"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:31Z","timestamp":1760122111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":240,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24055010"],"URL":"https:\/\/doi.org\/10.3390\/ijms24055010","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]}}}